Advertisement
JBIO vs KNSA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JBIO is a Buy and KNSA is a Hold.
JBIO's RSI Indicator ascends from oversold territory
The RSI Oscillator for JBIO moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 20 similar instances when the indicator left oversold territory. In 20 of the 20 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on JBIO as a result. In 77 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for JBIO just turned positive on October 08, 2026. Looking at past instances where JBIO's MACD turned positive, the stock continued to rise in 35 of 41 cases over the following month. The odds of a continued upward trend are 85%.
Following a +9.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where JBIO advanced for three days, in 223 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for JBIO moved below the 200-day moving average on October 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
JBIO broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JBIO entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.096) is normal, around the industry mean (3.037). P/E Ratio (-13.551) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. JBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
KNSA in downward trend: price dove below 50-day moving average on October 23, 2026
KNSA moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend. In 23 of 30 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 77%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for KNSA moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 48 similar instances where the indicator moved out of overbought territory. In 31 of the 48 cases, the stock moved lower in the following days. This puts the odds of a move lower at 65%.
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KNSA as a result. In 69 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for KNSA turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 27 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 63%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KNSA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for KNSA entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 10-day moving average for KNSA crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +5.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where KNSA advanced for three days, in 232 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
KNSA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. KNSA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.705) is normal, around the industry mean (8.413). P/E Ratio (68.849) is within average values for comparable stocks, (-1.728). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (7.564) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
KNSA | ||
|---|---|---|
OUTLOOK RATING 1..100 | 36 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 3 | |
SMR RATING 1..100 | 59 | |
PRICE GROWTH RATING 1..100 | 36 | |
P/E GROWTH RATING 1..100 | 96 | |
SEASONALITY SCORE 1..100 | 46 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| JBIO | KNSA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 65% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 84% | 2 days ago 72% |
| MACD ODDS (%) | 2 days ago 85% | 2 days ago 63% |
| TrendWeek ODDS (%) | 2 days ago 84% | 2 days ago 73% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 74% |
| Advances ODDS (%) | 7 days ago 82% | 8 days ago 76% |
| Declines ODDS (%) | 2 days ago 89% | 2 days ago 74% |
| BollingerBands ODDS (%) | 2 days ago 82% | 2 days ago 89% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 69% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JBIO’s FA Score shows that 2 FA rating(s) are green while KNSA’s FA Score has 1 green FA rating(s).
- JBIO’s FA Score: 2 green, 3 red.
- KNSA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JBIO’s TA Score shows that 4 TA indicator(s) are bullish while KNSA’s TA Score has 4 bullish TA indicator(s).
- JBIO’s TA Score: 4 bullish, 5 bearish.
- KNSA’s TA Score: 4 bullish, 6 bearish.
Price Growth
JBIO (@Biotechnology) experienced а +4.84% price change this week, while KNSA (@Pharmaceuticals: Generic) price change was -8.18% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -15.42%, and the average quarterly price growth was -14.11%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +79.23%. For the same industry, the average monthly price growth was -4.91%, and the average quarterly price growth was +6.36%.
Reported Earning Dates
JBIO is expected to report earnings on Nov 12, 2026.
KNSA is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Biotechnology (-0.45% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (+79.23% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
JBIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, JBIO has been loosely correlated with ARVN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if JBIO jumps, then ARVN could also see price increases.
| Ticker / NAME | Correlation To JBIO | 1D Price Change % | ||
|---|---|---|---|---|
| JBIO | 100% | -0.62% | ||
| ARVN - JBIO | 43% Loosely correlated | +0.14% | ||
| IMNM - JBIO | 43% Loosely correlated | -0.56% | ||
| SYRE - JBIO | 42% Loosely correlated | +2.86% | ||
| KURA - JBIO | 40% Loosely correlated | +0.10% | ||
| EDIT - JBIO | 40% Loosely correlated | N/A | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SCHK | 36.76 | 0.27 | +0.74% |
| Schwab 1000 Index ETF (SCHK) | |||
| ETJ | 7.93 | 0.02 | +0.25% |
| Eaton Vance Risk - Managed Diversified Equity Income Fund | |||
| FFIU | 20.99 | 0.04 | +0.19% |
| UVA Unconstrained Medium-Term Fixed Income ETF (FFIU) | |||
| AGZD | 22.55 | -0.02 | -0.10% |
| WisdomTree Interest Rate Hedged U.S. Aggregate Bond Fund (AGZD) | |||
| YFYA | 9.64 | -0.04 | -0.41% |
| Yields for You Strategy A ETF | |||